<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02420691</url>
  </required_header>
  <id_info>
    <org_study_id>2014-0371</org_study_id>
    <secondary_id>NCI-2015-01017</secondary_id>
    <secondary_id>2014-0371</secondary_id>
    <secondary_id>P30CA016672</secondary_id>
    <nct_id>NCT02420691</nct_id>
  </id_info>
  <brief_title>Ribociclib in Treating Patients With Advanced Neuroendocrine Tumors of Foregut Origin</brief_title>
  <official_title>A Phase II Study of LEE011 (Ribociclib) in Patients With Advanced Neuroendocrine Tumors of Foregut Origin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial studies how well ribociclib works in treating patients with&#xD;
      neuroendocrine tumors of the foregut, which includes the thymus, lung, stomach, and pancreas,&#xD;
      that have spread to other places in the body and usually cannot be cured or controlled with&#xD;
      treatment (advanced tumors). Ribociclib may stop the growth of tumor cells by blocking some&#xD;
      of the enzymes needed for cell growth.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To estimate the Response Evaluation Criteria in Solid Tumors (RECIST) (per version 1.1)&#xD;
      objective response rate of LEE011 (ribociclib) among patients with advanced foregut&#xD;
      neuroendocrine tumors (NETs).&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To evaluate the progression free survival duration of LEE011 among patients with advanced&#xD;
      foregut NETs.&#xD;
&#xD;
      II. To evaluate the safety and tolerability of LEE011 in patients with advanced foregut NETs.&#xD;
&#xD;
      III. To determine clinic benefit rate at 6 months (defined as complete response plus partial&#xD;
      response plus stable disease) with LEE011 among patients with advanced foregut NETs.&#xD;
&#xD;
      EXPLORATORY OBJECTIVES:&#xD;
&#xD;
      I. To determine baseline molecular markers (mutations, deletions, and amplifications in&#xD;
      multiple endocrine neoplasia [MEN]1, p27, p16 and cyclin D1 [CCND1]) in archival tumor that&#xD;
      may predict clinical benefit at 6 months from LEE011.&#xD;
&#xD;
      II. To determine potential mechanisms/markers of resistance. III. To determine early&#xD;
      chromogranin and neuron specific enolase responses in patients with elevated levels at&#xD;
      baseline.&#xD;
&#xD;
      IV. To determine the pharmacodynamic changes including proliferation-related Ki-67 antigen&#xD;
      (Ki-67) and phosphorylated retinoblastoma (pRb) upon treatment with LEE011 in patients with&#xD;
      advanced foregut NETs.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Patients receive ribociclib orally (PO) once daily (QD) on days 1-21. Courses repeat every 28&#xD;
      days in the absence of disease progression or unacceptable toxicity.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 25, 2015</start_date>
  <completion_date type="Actual">June 5, 2019</completion_date>
  <primary_completion_date type="Actual">June 5, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Response Rate Per Response Evaluation Criteria in Solid Tumors Version 1.1</measure>
    <time_frame>3 years 10 months</time_frame>
    <description>Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Clinical Benefit Rate</measure>
    <time_frame>At 6 months</time_frame>
    <description>Number of Participants that did not have progressive disease at 6 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, up to 24 months</time_frame>
    <description>PFS is the length of time during and after the treatment that a participant lives with the disease but it does not get worse.The Kaplan-Meier (KM) method will be used to estimate the PFS.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in pRB With Treatment</measure>
    <time_frame>Baseline (Pre-Treatment) and Cycle 2 Day 1, each Cycle is 28 days</time_frame>
    <description>Decrease in pRB as Measured by Immunohistochemistry (IHC) in Biopsies From Baseline and From cycle 2 day 1. H-scores were calculated as the sum of the products of the percentage of positive staining areas and the staining intensity (0, 1, 2 or 3), and ranged from 0 to 300. A score of 0 represents the absence of expression, and an H-score of 300 represents maximum expression.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in Ki-67 With Treatment</measure>
    <time_frame>Baseline (Pre-Treatment) and Cycle 2 Day 1, each Cycle is 28 days</time_frame>
    <description>Ki-67 was calculated as a percentage cells staining positive by Immunohistochemistry (IHC).</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Advanced Digestive System Neuroendocrine Neoplasm</condition>
  <condition>Duodenal Neuroendocrine Tumor G1</condition>
  <condition>Functional Pancreatic Neuroendocrine Tumor</condition>
  <condition>Gastric Neuroendocrine Tumor</condition>
  <condition>Intermediate Grade Lung Neuroendocrine Neoplasm</condition>
  <condition>Low Grade Lung Neuroendocrine Neoplasm</condition>
  <condition>Nonfunctional Pancreatic Neuroendocrine Tumor</condition>
  <condition>Thymus Neoplasm</condition>
  <arm_group>
    <arm_group_label>Treatment (ribociclib)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive ribociclib PO QD on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (ribociclib)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Pharmacological Study</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (ribociclib)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribociclib</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (ribociclib)</arm_group_label>
    <other_name>Kisqali</other_name>
    <other_name>LEE-011</other_name>
    <other_name>LEE011</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically or cytologically confirmed low or intermediate grade, unresectable well&#xD;
             differentiated foregut neuroendocrine tumors (thymic, bronchopulmonary, gastric,&#xD;
             duodenal and pancreatic); patients with multiple neuroendocrine tumors associated with&#xD;
             MEN1 syndrome will be eligible&#xD;
&#xD;
          -  Patients must have radiographically measurable disease&#xD;
&#xD;
          -  Pancreatic neuroendocrine patients must have had progression after prior therapy;&#xD;
             patients with other foregut neuroendocrine tumors must have had progressive disease&#xD;
             over the last 12 months, irrespective of prior therapy; patients with both functional&#xD;
             (who may continue somatostatin analogues as required for control of related symptoms)&#xD;
             and non-functional tumors are eligible; in patients who have previously received&#xD;
             therapy, the number of prior lines of therapy should not be more than 2 lines of&#xD;
             systemic therapy not including somatostatin analogues&#xD;
&#xD;
          -  Written informed consent must be obtained prior to any screening procedures&#xD;
&#xD;
          -  Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of&#xD;
             0 - 1&#xD;
&#xD;
          -  A sufficient interval must have elapsed between the last dose of prior anti-cancer&#xD;
             therapy (including cytotoxic and biological therapies and major surgery) and&#xD;
             enrollment, to allow the effects of prior therapy to have abated: a) cytotoxic or&#xD;
             targeted chemotherapy: greater than or equal to the duration of the cycle of the most&#xD;
             recent treatment regimen (a minimum of 3 weeks for all regimens, except 6 weeks for&#xD;
             nitrosoureas and mitomycin-C); b) biologic therapy (e.g., antibodies): greater than or&#xD;
             equal to 4 weeks&#xD;
&#xD;
          -  Absolute neutrophil count (ANC) greater than or equal to 1.5 x 10^9/L&#xD;
&#xD;
          -  Hemoglobin (Hgb) greater than or equal to 9 g/dL&#xD;
&#xD;
          -  Platelets greater than or equal to 100 x 10^9/L&#xD;
&#xD;
          -  Serum total bilirubin less than or equal to 1.5 x upper limit of normal (ULN)&#xD;
&#xD;
          -  Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) and&#xD;
             alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) less&#xD;
             than or equal to 2.5 x ULN, except in patients with tumor involvement of the liver who&#xD;
             must have AST and ALT less than or equal to 5 x ULN&#xD;
&#xD;
          -  Serum creatinine less than or equal to 1.5 x ULN or 24-hour clearance greater than or&#xD;
             equal to 50 mL/min&#xD;
&#xD;
          -  Serum potassium (corrected for serum albumin) must be within clinically relevant&#xD;
             limits (e.g., a patient can be enrolled if a lab value may be outside the normal&#xD;
             laboratory range but the abnormality is not clinically relevant or can be repleted)&#xD;
&#xD;
          -  Sodium (corrected for serum albumin) must be within clinically relevant limits (e.g.,&#xD;
             a patient can be enrolled if a lab value may be outside the normal laboratory range&#xD;
             but the abnormality is not clinically relevant or can be repleted)&#xD;
&#xD;
          -  Magnesium (corrected for serum albumin) must be within clinically relevant limits&#xD;
             (e.g., a patient can be enrolled if a lab value may be outside the normal laboratory&#xD;
             range but the abnormality is not clinically relevant or can be repleted)&#xD;
&#xD;
          -  Phosphorus (corrected for serum albumin) must be within clinically relevant limits&#xD;
             (e.g., a patient can be enrolled if a lab value may be outside the normal laboratory&#xD;
             range but the abnormality is not clinically relevant or can be repleted)&#xD;
&#xD;
          -  Total calcium (corrected for serum albumin) must be within clinically relevant limits&#xD;
             (e.g., a patient can be enrolled if a lab value may be outside the normal laboratory&#xD;
             range but the abnormality is not clinically relevant or can be repleted)&#xD;
&#xD;
          -  Negative pregnancy test (serum beta-human chorionic gonadotropin [B-HCG]) within 7&#xD;
             days of starting study treatment is required in women of childbearing potential; NET&#xD;
             patients with positive B-HCG are eligible if pregnancy can be excluded by vaginal&#xD;
             ultrasound or lack of expected doubling of B-HCG&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient has a known hypersensitivity to LEE011 or any of its excipients&#xD;
&#xD;
          -  Patients with known or suspected brain metastases; however, if radiation therapy&#xD;
             and/or surgery has been completed and serial evaluation by computed tomography (CT)&#xD;
             (with contrast enhancement) or magnetic resonance imaging (MRI) over a minimum of 3&#xD;
             months demonstrates the disease to be stable and if the patient remains asymptomatic,&#xD;
             then the patient may be enrolled; such patients must have no need for treatment with&#xD;
             steroids or anti-epileptic medications&#xD;
&#xD;
          -  Patients with concurrent malignancies or malignancies within 3 years prior to starting&#xD;
             study drug (with the exception of tumors common to a single genetic cancer syndrome,&#xD;
             i.e. MEN1, MEN2, von Hippel-Lindau [vHL], tuberous sclerosis complex [TSC] etc., or&#xD;
             adequately treated, basal cell skin cancer, squamous cell carcinoma, non-melanoma skin&#xD;
             cancer or curatively resected cervical cancer)&#xD;
&#xD;
          -  Patient is not able to swallow oral medication and/or has impairment of&#xD;
             gastrointestinal (GI) function or GI disease that may significantly alter the&#xD;
             absorption of the study drugs (e.g., ulcerative diseases, uncontrolled nausea,&#xD;
             vomiting, diarrhea, malabsorption syndrome, or small bowel resection)&#xD;
&#xD;
          -  Known diagnosis of human immunodeficiency virus (HIV) or hepatitis C (testing is not&#xD;
             mandatory)&#xD;
&#xD;
          -  Patient has any other concurrent severe and/or uncontrolled medical condition that&#xD;
             would, in the investigator's judgment, contraindicate patient participation in the&#xD;
             clinical study (e.g. chronic pancreatitis, chronic active hepatitis, etc.)&#xD;
&#xD;
          -  Patient who has received radiotherapy within less than or equal to 4 weeks or limited&#xD;
             field radiation for palliation within less than or equal to 2 weeks prior to starting&#xD;
             study drug, and who has not recovered to grade 1 or better from related side effects&#xD;
             of such therapy (exceptions include alopecia) and/or in whom greater than or equal to&#xD;
             30% of the bone marrow was irradiated&#xD;
&#xD;
          -  Patient has had major surgery within 14 days prior to starting study drug or has not&#xD;
             recovered from major side effects (tumor biopsy is not considered as major surgery)&#xD;
&#xD;
          -  Impaired cardiac function or clinically significant cardiac diseases, including any of&#xD;
             the following: a) history of acute coronary syndromes (including myocardial&#xD;
             infarction, unstable angina, coronary artery bypass grafting, coronary angioplasty, or&#xD;
             stenting) or symptomatic pericarditis less than 12 months prior to screening b)&#xD;
             history of documented congestive heart failure (New York Heart Association functional&#xD;
             classification III-IV) c) documented cardiomyopathy d) patient has a left ventricular&#xD;
             ejection fraction (LVEF) less than 50% as determined by multiple gated acquisition&#xD;
             (MUGA) scan or echocardiogram (ECHO) at screening e) history of ventricular,&#xD;
             supraventricular, nodal arrhythmias, or any other cardiac arrhythmias, long QT&#xD;
             syndrome or conduction abnormality within 12 months prior to starting study drug f)&#xD;
             congenital long QT syndrome or a family history of corrected QT interval (QTc)&#xD;
             prolongation g) on screening, inability to determine the corrected QT for Fridericia&#xD;
             (QTcF) interval on the electrocardiogram (ECG) (i.e.: unreadable or not interpretable)&#xD;
             or QTcF &gt; 450 msec (using Fridericia's correction); all as determined by screening ECG&#xD;
             (mean of triplicate ECGs)&#xD;
&#xD;
          -  Systolic blood pressure greater than 160 mmHg or less than 90 mmHg at screening&#xD;
&#xD;
          -  Patients who are currently receiving treatment with agents that are known to cause QTc&#xD;
             prolongation or inducing Torsade de Pointes in humans and are unable to discontinue or&#xD;
             switch to an alternate medication&#xD;
&#xD;
          -  Patients who are currently receiving treatment (within 5 days prior to starting study&#xD;
             drug) with agents that are known strong inducers or inhibitors of cytochrome P450,&#xD;
             family 3, subfamily A polypeptide 4 (CYP3A4)/cytochrome P450, family 3, subfamily A&#xD;
             polypeptide 5 (5), or that have a narrow therapeutic window and are predominantly&#xD;
             metabolized through CYP3A4/5&#xD;
&#xD;
          -  Patients with concurrent severe and/or uncontrolled concurrent medical conditions that&#xD;
             could compromise participation in the study (e.g., uncontrolled diabetes mellitus&#xD;
             defined by a glucose greater than 1.5 ULN in spite of adequate medical treatment,&#xD;
             clinically significant pulmonary disease, clinically significant neurological&#xD;
             disorder, active or uncontrolled infection)&#xD;
&#xD;
          -  Patient has a history of non-compliance to medical regimen or inability to grant&#xD;
             consent&#xD;
&#xD;
          -  Pregnant or lactating women, where pregnancy is defined as the state of a female after&#xD;
             conception and until the termination of gestation, confirmed by a positive hCG&#xD;
             laboratory test (greater than 5 mIU/mL)&#xD;
&#xD;
          -  Women of child-bearing potential, defined as all women physiologically capable of&#xD;
             becoming pregnant, unless they are using effective methods of contraception throughout&#xD;
             the study and for 8 weeks after study drug discontinuation; highly effective&#xD;
             contraception methods include: total abstinence when this is in line with the&#xD;
             preferred and usual lifestyle of the patient; periodic abstinence (e.g., calendar,&#xD;
             ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable&#xD;
             methods of contraception; female sterilization (have had surgical bilateral&#xD;
             oophorectomy with or without hysterectomy) or tubal ligation at least six weeks before&#xD;
             taking study treatment; in case of oophorectomy alone, only when the reproductive&#xD;
             status of the woman has been confirmed by follow up hormone level assessment; male&#xD;
             sterilization (at least 6 months prior to screening); for female patients on the&#xD;
             study, the vasectomized male partner should be the sole partner for that patient;&#xD;
             combination of any of the two following (a+b or a+c or b+c) a. use of oral, injected&#xD;
             or implanted hormonal methods of contraception or other forms of hormonal&#xD;
             contraception that have comparable efficacy (failure rate &lt; 1%), for example hormone&#xD;
             vaginal ring or transdermal hormone contraception b. placement of an intrauterine&#xD;
             device (IUD) or intrauterine system (IUS) c. barrier methods of contraception: condom&#xD;
             or occlusive cap (diaphragm or cervical/vault caps) with spermicidal&#xD;
             foam/gel/film/cream/vaginal suppository; in case of use of oral contraception, women&#xD;
             should have been stable on the same pill before taking study treatment; note: oral&#xD;
             contraceptives are allowed but should be used in conjunction with a barrier method of&#xD;
             contraception; women are considered post-menopausal and not of child bearing potential&#xD;
             if they have had 12 months of natural (spontaneous) amenorrhea with an appropriate&#xD;
             clinical profile (e.g. age appropriate, history of vasomotor symptoms) or have had&#xD;
             surgical bilateral oophorectomy (with or without hysterectomy) or tubal ligation at&#xD;
             least six weeks ago; in the case of oophorectomy alone, only when the reproductive&#xD;
             status of the woman has been confirmed by follow up hormone level assessment is she&#xD;
             considered not of child bearing potential&#xD;
&#xD;
          -  Sexually active males unless they use a condom during intercourse while taking the&#xD;
             drug and for 21 days after stopping treatment and should not father a child in this&#xD;
             period; a condom is required to be used also by vasectomized men in order to prevent&#xD;
             delivery of the drug via seminal fluid&#xD;
&#xD;
          -  Patients unwilling or unable to comply with the protocol&#xD;
&#xD;
          -  Patient is currently receiving warfarin or other coumarin-derived anticoagulant for&#xD;
             treatment, prophylaxis or otherwise; therapy with heparin, low molecular weight&#xD;
             heparin (LMWH) or fondaparinux is allowed&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nageshwara V Dasari</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>University of Texas MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>April 15, 2015</study_first_submitted>
  <study_first_submitted_qc>April 15, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 20, 2015</study_first_posted>
  <results_first_submitted>July 10, 2020</results_first_submitted>
  <results_first_submitted_qc>October 8, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">October 30, 2020</results_first_posted>
  <last_update_submitted>October 8, 2020</last_update_submitted>
  <last_update_submitted_qc>October 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Neuroendocrine Tumors</mesh_term>
    <mesh_term>Adenoma, Islet Cell</mesh_term>
    <mesh_term>Thymus Neoplasms</mesh_term>
    <mesh_term>Thymoma</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 19, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/91/NCT02420691/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>September 2015-August 2016. All patients enrolled at MD Anderson.</recruitment_details>
      <pre_assignment_details>21 participants consented, 1 participant was not eligible due to screen failure.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Study Participants</title>
          <description>LEE011 will be taken orally, once a day for 21 consecutive days followed by a 7 day planned break. LEE011 will be dosed on a flat dosing scale of 600 mg/day, irrespective of size and weight.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Study Participants</title>
          <description>LEE011 will be taken orally, once a day for 21 consecutive days followed by a 7 day planned break. LEE011 will be dosed on a flat dosing scale of 600 mg/day, irrespective of size and weight.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57" lower_limit="29" upper_limit="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Response Rate Per Response Evaluation Criteria in Solid Tumors Version 1.1</title>
        <description>Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.</description>
        <time_frame>3 years 10 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Study Participants</title>
            <description>LEE011 will be taken orally, once a day for 21 consecutive days followed by a 7 day planned break. LEE011 will be dosed on a flat dosing scale of 600 mg/day, irrespective of size and weight.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Response Rate Per Response Evaluation Criteria in Solid Tumors Version 1.1</title>
          <description>Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Clinical Benefit Rate</title>
        <description>Number of Participants that did not have progressive disease at 6 months.</description>
        <time_frame>At 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Study Participants</title>
            <description>LEE011 will be taken orally, once a day for 21 consecutive days followed by a 7 day planned break. LEE011 will be dosed on a flat dosing scale of 600 mg/day, irrespective of size and weight.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinical Benefit Rate</title>
          <description>Number of Participants that did not have progressive disease at 6 months.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression Free Survival (PFS)</title>
        <description>PFS is the length of time during and after the treatment that a participant lives with the disease but it does not get worse.The Kaplan-Meier (KM) method will be used to estimate the PFS.</description>
        <time_frame>From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, up to 24 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Study Participants</title>
            <description>LEE011 will be taken orally, once a day for 21 consecutive days followed by a 7 day planned break. LEE011 will be dosed on a flat dosing scale of 600 mg/day, irrespective of size and weight.</description>
          </group>
        </group_list>
        <measure>
          <title>Progression Free Survival (PFS)</title>
          <description>PFS is the length of time during and after the treatment that a participant lives with the disease but it does not get worse.The Kaplan-Meier (KM) method will be used to estimate the PFS.</description>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.44" lower_limit="7.37" upper_limit="13.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in pRB With Treatment</title>
        <description>Decrease in pRB as Measured by Immunohistochemistry (IHC) in Biopsies From Baseline and From cycle 2 day 1. H-scores were calculated as the sum of the products of the percentage of positive staining areas and the staining intensity (0, 1, 2 or 3), and ranged from 0 to 300. A score of 0 represents the absence of expression, and an H-score of 300 represents maximum expression.</description>
        <time_frame>Baseline (Pre-Treatment) and Cycle 2 Day 1, each Cycle is 28 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Study Participants</title>
            <description>LEE011 will be taken orally, once a day for 21 consecutive days followed by a 7 day planned break. LEE011 will be dosed on a flat dosing scale of 600 mg/day, irrespective of size and weight.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in pRB With Treatment</title>
          <description>Decrease in pRB as Measured by Immunohistochemistry (IHC) in Biopsies From Baseline and From cycle 2 day 1. H-scores were calculated as the sum of the products of the percentage of positive staining areas and the staining intensity (0, 1, 2 or 3), and ranged from 0 to 300. A score of 0 represents the absence of expression, and an H-score of 300 represents maximum expression.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H- Score Pre-Treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="236.47" spread="67.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H-Score Post-Treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="238.32" spread="39.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in Ki-67 With Treatment</title>
        <description>Ki-67 was calculated as a percentage cells staining positive by Immunohistochemistry (IHC).</description>
        <time_frame>Baseline (Pre-Treatment) and Cycle 2 Day 1, each Cycle is 28 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Study Participants</title>
            <description>LEE011 will be taken orally, once a day for 21 consecutive days followed by a 7 day planned break. LEE011 will be dosed on a flat dosing scale of 600 mg/day, irrespective of size and weight.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Ki-67 With Treatment</title>
          <description>Ki-67 was calculated as a percentage cells staining positive by Immunohistochemistry (IHC).</description>
          <units>percentage of cells</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-Treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.61" spread="10.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-Treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.11" spread="17.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3 years and 5 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Study Participants</title>
          <description>LEE011 will be taken orally, once a day for 21 consecutive days followed by a 7 day planned break. LEE011 will be dosed on a flat dosing scale of 600 mg/day, irrespective of size and weight.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Upper Gastrointestinal Hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Non-cardiac Chest Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoglycemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Kidney Injury</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumothroax</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Thromboembolic Event</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye Disorders: Other- Periorbital Swelling and Crystal Discharge</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Gastroparesis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Abdominal Distention</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Gastroesophageal Reflux Disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Mucositis Oral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Edema Limbs</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Edema Face</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Neutrophil Count Increased</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Platelet Count Decreased</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Creatinine Increased</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Alanine Aminotransferase Increased</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Aspartate Aminotransferase Increased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Weight Loss</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Alkaline Phosphatase Increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Blood Bilirubin Increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Investigations: Other- Hyperphosphatemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Hypophosphatemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Hypomagnesemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Hyperphosphatemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dysguesia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Peripheral Sensory Neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Kidney Injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Nasal Congestion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash Maculo-papular</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Dry Skin</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Arvind Dasari,MBBS</name_or_title>
      <organization>UT MD Anderson Cancer Center</organization>
      <phone>713-792-2828</phone>
      <email>adasari@mdanderson.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

